{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T18:58:55Z","timestamp":1778957935412,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"instituto de salud carlos iii","doi-asserted-by":"publisher","award":["CP16\/00916; PI18\/01188; and RD16\/0012\/0014"],"award-info":[{"award-number":["CP16\/00916; PI18\/01188; and RD16\/0012\/0014"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"european regional development fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>In this pandemic, it is essential for rheumatologists and patients to know the relationship between COVID-19 and inflammatory rheumatic diseases (IRDs). We wanted to assess the role of targeted synthetic or biologic disease-modifying antirheumatic drugs (ts\/bDMARDs) and other variables in the development of moderate-severe COVID-19 disease in IRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An observational longitudinal study was conducted during the epidemic peak in Madrid (1 March to 15 April 2020). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid with a medical diagnosis of IRD were included. Main outcome: hospital admission related to COVID-19. Independent variable: ts\/bDMARDs. Covariates: sociodemographic, comorbidities, type of IRD diagnosis, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Incidence rate (IR) of hospital admission related to COVID-19 was expressed per 1000 patient-months. Cox multiple regression analysis was run to examine the influence of ts\/bDMARDs and other covariates on IR of hospital admission related to COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 3951 IRD patients were included (5896 patient-months). Methotrexate was the csDMARD most used. Eight hundred and two patients were on ts\/bDMARDs, mainly anti-TNF agents, and Rtx. Hospital admissions related to COVID-19 occurred in 54 patients (1.36%) with an IR of 9.15 (95% confidence interval: 7\u201311.9). In the multivariate analysis, older, male, comorbidities, and specific systemic autoimmune conditions (Sj\u00f6gren, polychondritis, Raynaud, and mixed connective tissue disease) had more risk of hospital admissions. Exposition to ts\/bDMARDs did not achieve statistical significance. Use of glucocorticoids, NSAIDs, and csDMARDs dropped from the final model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study provides additional evidence in IRD patients regarding susceptibility to moderate\u2013severe infection related to COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x20962692","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T02:46:49Z","timestamp":1612838809000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6126-8786","authenticated-orcid":false,"given":"Benjamin","family":"Fernandez-Gutierrez","sequence":"first","affiliation":[{"name":"Rheumatology Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-0545","authenticated-orcid":false,"given":"Leticia","family":"Leon","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IDISSC), Hospital Cl\u00ednico San Carlos, Martin Lagos s\/n, Madrid, 28040, Spain Universidad Camilo Jose Cela, Madrid, Spain"},{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Madrid","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Rodriguez-Rodriguez","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalifer","family":"Freites","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Font","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkaitz","family":"Mucientes","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Culebras","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio","family":"Colome","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Angel","family":"Jover","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Cl\u00ednico San Carlos, Madrid, and Medicine Department, Universidad Complutense, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Abasolo","sequence":"additional","affiliation":[{"name":"Rheumatology Department and IDISSC, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"bibr1-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2020.04.001"},{"key":"bibr2-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"bibr3-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"bibr4-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.021"},{"key":"bibr5-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"bibr6-1759720X20962692","unstructured":"American College of Rheumatology. Clinical guideline for adult patients with rheumatic diseases, https:\/\/www.rheumatology.org\/Announcements#ClinicalGuidance (accessed 8 May 2020)."},{"key":"bibr7-1759720X20962692","unstructured":"European League Against Rheumatism. Guidance for patients COVID-19, https:\/\/www.eular.org\/eular_guidance_for_patients_covid19_outbreak.cfm (accessed 8 May 2020)."},{"key":"bibr8-1759720X20962692","unstructured":"National institute for Health and Care Excellence. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167), https:\/\/www.nice.org.uk\/guidance\/ng167\/chapter\/1-Communicating-with-patients-and-minimising-risk (2020, accessed 8 May 2020)."},{"key":"bibr9-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102523"},{"key":"bibr10-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217424"},{"key":"bibr11-1759720X20962692","doi-asserted-by":"crossref","unstructured":"Michelena X, Borrell H, Lopez-Corbeto M, et al Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. 2020; 50: 564\u2013570.","DOI":"10.1016\/j.semarthrit.2020.05.001"},{"key":"bibr12-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1002\/ART.41388."},{"key":"bibr13-1759720X20962692","unstructured":"Hospital Cl\u00ednico San Carlos. Memoria 2018, https:\/\/www.comunidad.madrid\/sites\/default\/files\/doc\/sanidad\/memo\/hosp-memoria-2018_hclinico_ok.pdf (2018, accessed 8 May 2020)."},{"key":"bibr14-1759720X20962692","unstructured":"COVID-19. Situaci\u00f3n actual en la Comunidad de Madrid. Informe de situaci\u00f3n del 8 de Mayo, https:\/\/www.comunidad.madrid\/sites\/default\/files\/doc\/sanidad\/200508cam_covid19.pdf (2020, accessed 8 May 2020)."},{"key":"bibr15-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102575"},{"key":"bibr16-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217615."},{"key":"bibr17-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200507"},{"key":"bibr18-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009567."},{"key":"bibr19-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"bibr20-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.20040758."},{"key":"bibr21-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047"},{"key":"bibr22-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217690."},{"key":"bibr23-1759720X20962692","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217566"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X20962692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X20962692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X20962692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:36:59Z","timestamp":1777588619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X20962692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":23,"alternative-id":["10.1177\/1759720X20962692"],"URL":"https:\/\/doi.org\/10.1177\/1759720x20962692","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.21.20108696","asserted-by":"object"}]},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"1759720X20962692"}}